Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA.
J Exp Clin Cancer Res. 2009 Aug 14;28(1):113. doi: 10.1186/1756-9966-28-113.
Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck, and non-small cell lung cancer. However, due to the relatively recent addition of biologic compounds to the therapeutic arsenal, information related to adverse reactions is less well known than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated as the most frequent side effect cited during cetuximab therapy for malignancy; however, other effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead to significant morbidity and mortality. The purpose of this review is to compile the various pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to compare the incidence of these adverse reactions to standard therapies.
生物来源的化合物，或生物制剂，在恶性肿瘤的治疗中越来越多地被用作治疗剂。越来越多地利用生物制剂开发抗癌靶向治疗药物。西妥昔单抗是一种嵌合单克隆抗体，是一种抗癌靶向治疗药物，已显示出在减缓结直肠癌、头颈部和非小细胞肺癌患者疾病进展方面的疗效。然而，由于生物化合物最近才被添加到治疗武器库中，与传统化疗药物相比，有关不良反应的信息知之甚少。已经证明皮肤反应是在使用西妥昔单抗治疗恶性肿瘤时最常报道的副作用;然而，其他影响可能导致更大的发病率。一般来说，治疗药物的肺部并发症可导致严重的发病率和死亡率。本综述的目的是总结在各种恶性肿瘤中使用西妥昔单抗治疗的患者中出现的各种肺部副作用，并将这些不良反应的发生率与标准治疗进行比较。
